FUROSEMIDE | N018902 | FRESENIUS KABI USA LLC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from Mylan Pharmaceuticals Inc FDA-2016-P-1285 · 8 docket documents Mylan Pharmaceuticals Inc. filed this citizen petition pursuant to Section 505(j)(2)(C) of the Federal Food, Drug and Cosmetic Act requesting that the FDA declare Furosemide Injection, USP—10 mg/mL in 2 mL, 4 mL, and 10 mL fill suitable for submission as an ANDA, with designation of either Fresenius | Other | 2016-05-19 | Open | Mylan Pharmaceuticals Inc |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$0.4178
per ml
Lowest NADAC/Unit
$0.3189
per ml
Brand NDCs
0
Generic NDCs
5
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 63323028016FUROSEMIDE 20 MG/2 ML VIAL | $0.4178 | ML | Generic | — | 2026-06-17 |
| 63323028002FUROSEMIDE 20 MG/2 ML VIAL | $0.4178 | ML | Generic | — | 2026-06-17 |
| 81565020102FUROSEMIDE 20 MG/2 ML VIAL | $0.4178 | ML | Generic | — | 2026-06-17 |
| 63323028004FUROSEMIDE 40 MG/4 ML VIAL | $0.3189 | ML | Generic | — | 2026-06-17 |
| 63323028026FUROSEMIDE 40 MG/4 ML VIAL | $0.3189 | ML | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.